By Jeremiah Velasquez, FNP-BC, AGACNP-BC
Founder, Steel City HRT & Weight Loss | Board-Certified Family & Acute Care Nurse Practitioner
NPI: 1841894003
Medically reviewed by Jeremiah Velasquez, FNP-BC | Last reviewed: July 15, 2026

Summary: Long-term aromatase inhibitor use during testosterone replacement therapy can reduce spinal bone mineral density and contribute to joint stiffness in men, because estradiol — not just testosterone — plays a direct role in maintaining bone and cartilage health. A one-year randomized trial found that spinal bone density declined in men taking an aromatase inhibitor, whereas it increased in men who did not.

Why Do Men on TRT End Up on an Aromatase Inhibitor for Years, Not Weeks?

Once an aromatase inhibitor gets added to a TRT protocol, it rarely gets reevaluated — it just becomes part of the routine. Your provider isn't wrong for wanting to control estrogen-related symptoms. The system is wrong for leaving that prescription running for years without asking whether it's still needed.

Aromatase is the enzyme that converts a portion of testosterone into estradiol, the primary estrogen in men. When a TRT protocol includes an aromatase inhibitor like anastrozole, it blocks that conversion — which lowers estradiol while pushing testosterone higher on paper. That tradeoff might make sense short-term for a man with genuine high-estrogen symptoms. It becomes a different problem when the prescription runs unchecked for two, three, five years.

Long-volume clinics rarely build in a reassessment. One. The AI gets added at TRT initiation as a default, not a response to symptoms. Two. Estradiol gets suppressed below what the body needs for skeletal and joint health. Three. No one checks a bone density scan or asks about new stiffness until a man is already dealing with it.

For men in Scottsdale staying active through Arizona's long outdoor season — golf, hiking South Mountain, keeping up with kids on the weekend — new joint stiffness or aching hands often gets chalked up to overuse or getting older, when a years-long aromatase inhibitor prescription may be the actual driver.

Key takeaway: An aromatase inhibitor added at the initiation of TRT often remains in place for years without reassessment, even after the original reason for prescribing it has disappeared.

How Does Suppressing Estrogen for Years Actually Damage Bone and Joint Health?

Here's what most people don't know: estradiol is one of the primary hormones responsible for maintaining bone density in men, not just women. Estrogen slows the activity of the cells that break down bone and supports the cells that build it back up. Take estradiol too low for too long, and that balance tips toward bone loss — regardless of how high testosterone reads on a lab report.

According to a one-year, double-blind, randomized, placebo-controlled trial published in the <em>Journal of Clinical Endocrinology & Metabolism</em>, 69 men aged 60 and older were given either 1 mg of anastrozole daily or a placebo. Testosterone rose from 319 to 474 ng/dL in the anastrozole group over the year, while estradiol dropped from 15 to 12 pg/mL. Spine bone mineral density decreased in the anastrozole group over that same year, while it increased in the placebo group — a statistically significant difference (P = 0.0014) (<a href="https://academic.oup.com/jcem/article/94/12/4785/2596582">Burnett-Bowie et al., 2009</a>).

"A man can watch his testosterone number climb on an aromatase inhibitor and think the protocol is working, while his bone density and his joints are quietly paying the price for it. We don't chase one number at the expense of everything else." — Jeremiah Velasquez, FNP-BC, AGACNP-BC, Founder of Steel City HRT & Weight Loss

Joint discomfort follows a similar mechanism. Aromatase is expressed directly in the chondrocytes and synovial tissue that make up joint cartilage — not just in fat and reproductive tissue. When estrogen production is suppressed there, inflammatory cytokines like IL-6 increase locally, and cartilage loses some of its natural protection against breakdown (Frontiers in Endocrinology, 2021). This mechanism is best documented in women taking aromatase inhibitors for breast cancer treatment, where up to half report new or worsening joint pain within a year of starting therapy — but the underlying biology, estrogen receptors sitting directly in cartilage, isn't sex-specific.

The table below summarizes the one-year bone density findings:

Key takeaway: A year of unnecessary aromatase inhibitor use can measurably reduce spine bone density in men, even while testosterone numbers improve.

What Does Responsible, Long-Term Estrogen Management Look Like on TRT?

Responsible estrogen management means treating an aromatase inhibitor as a targeted, reassessed tool — not a permanent fixture of a TRT protocol. Starting with a clear clinical reason before it's ever prescribed, followed by periodic reassessment of whether it's still needed, and ending with monitoring for the downstream effects — bone density and joint symptoms — that routine suppression can cause.

For men who genuinely need an aromatase inhibitor, that means the lowest effective dose, used only as long as symptoms warrant it. For the majority of men on TRT who don't have documented high-estrogen symptoms, it means never starting one in the first place. Either way, estradiol shouldn't be pushed to the floor and left there indefinitely. You've got two options: stay on a protocol that quietly works against your bones and joints for the sake of a number, or get one that's actually reassessed over time.

For Scottsdale and Gilbert men who want to keep moving — on the course, on the trail, or just keeping up at home — that reassessment isn't optional. It's the difference between a protocol built to last and one that costs you years down the road.

Key takeaway: An aromatase inhibitor should be reassessed regularly, not left running indefinitely once it's added to a TRT protocol.

Why Are Scottsdale Men Choosing Steel City HRT & Weight Loss for Long-Term TRT Care?

Steel City HRT & Weight Loss is LegitScript-certified and licensed to treat TRT patients throughout Arizona, including Scottsdale and Gilbert, entirely by telehealth. I have been the patient handed a prescription with no plan to ever revisit it, and I have been the provider who had to walk a man back from years of unnecessary estrogen suppression. That's why every protocol here gets reassessed, not just renewed.

Starting with a full baseline panel that includes estradiol alongside total and free testosterone, followed by regular lab review at each renewal, and ending with a conversation about whether an aromatase inhibitor is still doing more good than harm. We offer TRT/HRT, GLP-1 metabolic optimization, and peptide optimization — individualized to your labs, your symptoms, and your goals over time, not a protocol set once and forgotten.

Ready to Get Started? Scottsdale Men Can See a Provider This Week.

No waiting room, no drive across town, no protocol running on autopilot for years without a second look. Men in Scottsdale and Gilbert can complete labs and a telehealth consult without ever stepping into a clinic. You've got two options: stay on a plan that hasn't been reassessed since it started, or get one built to protect your bones and joints for the long run. Labs, consult, optimization — that easy. It all starts at steelcity-trt.com.

Frequently Asked Questions

Q: What causes bone density loss in men on long-term aromatase inhibitor therapy?
A: Aromatase inhibitors suppress estradiol, and estradiol directly regulates the bone-building and bone-breakdown cycle in men. A one-year randomized trial found spine bone density declined in men on an aromatase inhibitor while it increased in men on placebo.

Q: Can aromatase inhibitors cause joint pain in men on TRT?
A: Estrogen receptors exist directly in joint cartilage and synovial tissue, and estrogen suppression is linked to increased joint inflammation. This is best documented in women on aromatase inhibitors for breast cancer, but the underlying mechanism is not sex-specific.

Q: How does Steel City decide if I still need an aromatase inhibitor on TRT?
A: Steel City reviews estradiol alongside total and free testosterone at each lab renewal and reassesses whether an aromatase inhibitor remains clinically indicated, rather than continuing it indefinitely by default.

Q: Is it safe to stay on an aromatase inhibitor for years on TRT?
A: Long-term, unreassessed aromatase inhibitor use has been linked to reduced spine bone mineral density in men. It should be used at the lowest effective dose, only as long as symptoms warrant it, under clinical supervision.

Q: Can I get long-term TRT and estrogen management in Scottsdale without visiting a clinic?
A: Yes. Steel City HRT & Weight Loss provides fully telehealth TRT care to men in Scottsdale and throughout Arizona, including ongoing lab review and estrogen management without an in-person visit.

Q: Is Steel City HRT & Weight Loss available to men in Scottsdale, Arizona?
A: Yes. Steel City HRT & Weight Loss is LegitScript-certified and licensed to treat TRT patients throughout Arizona, including Scottsdale, entirely through telehealth.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed provider before beginning any hormone or weight loss therapy. Jeremiah Velasquez, FNP-BC, AGACNP-BC, is a licensed nurse practitioner. Steel City HRT & Weight Loss is a LegitScript-certified telehealth clinic.

How We Source This Content

The clinical information in this article is drawn from peer-reviewed medical literature, national clinical guidelines, and U.S. government and regulatory sources. Every post is written and medically reviewed by Jeremiah Velasquez, FNP-BC, AGACNP-BC, a board-certified nurse practitioner and founder of Steel City HRT & Weight Loss.

References

• Burnett-Bowie SM, et al. Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. J Clin Endocrinol Metab. 2009. academic.oup.com/jcem

• Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. Frontiers in Endocrinology. 2021. frontiersin.org

• Endocrine Society Clinical Practice Guidelines on Testosterone Therapy in Men with Hypogonadism. endocrine.org

Medically reviewed by Jeremiah Velasquez, FNP-BC, AGACNP-BC — Founder & Lead Clinician, Steel City HRT & Weight Loss. Dual board-certified nurse practitioner specializing in hormone optimization and metabolic health.